Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial

Psychopharmacology

Volumn 124, Issue 1-2, 1996, Pages 159-167

  Beasley Jr , Charles M ^a   Sanger, Todd ^a   Satterlee, Winston ^a   Tollefson, Gary ^a   Tran, Pierre ^a   Hamilton, Susan ^a   Green, Alan ^b   Dott, Sharon ^c   Pfister, Greg ^d   Roxas, Luisito ^d   Small, Joyce ^e   Thomas, Marshall ^f   Ames, Donna ^g   Schooler, Nina ^h   Baker, Robert ^h   Levine, Robert ⁱ   Fabre, Louis ^j   Friedel, Robert ^k   Safferman, Allen ^l   Lieberman, Jeffrey ^l   Stahl, Stephen ^m   more..

^a ELI LILLY AND COMPANY   (United States)

^b MASSACHUSETTS MENTAL HEALTH CENTER   (United States)

^c University of Texas Medical Branch School of Medicine   (United States)

^d St Alexius Medical Center   (United States)

^e INDIANA UNIVERSITY   (United States)

^f Colorado Psychiatric Hospital ^*  (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h Mayview State Hospital   (United States)

ⁱ Fabre Research Clinic Inc ^*

^j Fabre Research Clinic Inc   (United States)

^k UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^l ZUCKER HILLSIDE HOSPITAL   (United States)

^m Inst for Psychopharmacology Res   (United States)

more..

Author keywords

Acute; Antipsychotic; Atypical; Double blind; Olanzapine; Placebo; Schizophrenia

Indexed keywords

BENZATROPINE; BENZODIAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO;

ADULT; AKATHISIA; ANOREXIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEGATIVE SYNDROME; PARKINSONISM; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHIATRY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; SINGLE BLIND PROCEDURE; SYMPTOMATOLOGY;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PIRENZEPINE; SCHIZOPHRENIA;

EID: 0029930337     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02245617     Document Type: Article

References (22)

1. American Psychiatric Association Task Force on Nomenclature and Statistics (1987) Diagnostic and statistical manual of mental disorders, 3rd edn. revised. APA Press, Washington, DC
2. Barnes TR (1989) A rating scale for drug-induced akathisia. Br J Psychiatry 154:672-676
3. Beasley CM, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S, Olanzapine HGAD Study Group (1995) Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology (in press)
4. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT (1995) Radioreceptor binding profile of the atypical olanzapine. Neuropsychopharmacology (in press)
5. Casey DE (1989) Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology 99:S47-S53
6. Fuller RW, Snoddy HD (1992) Neuroendocrine evidence for antagonism of serotonin and dopamine receptors by olanzapine (LY170053), an antipsychotic drug candidate. Res Commun Chem Pathol Pharmacol 77:87-93
7. Guy W (1976) ECDEU assessment manual for psychopharmacology, revised version. US Department of Health, Education and Welfare, Bethesda, Maryland
8. Hemrick-Luecke SK, Bymaster FP, Falcone JF, Moore NA, Tye NC, Fuller RW (1993) Effect of olanzapine on rat brain receptor binding, acetylcholine levels and monoamine turnover. Tenth Annual Society for Neuroscience Meeting, Indianapolis Chapter Indianapolis, Ind. Twenty-third Annual Society for Neuroscience Meeting, Washington, DC, 21 May, 7-12 November
9. Kay SR, Opler LA, Fiszbein A (1986) Positive and negative syndrome scale (PANSS) manual. Multi-Health Systems, North Tonawanda, New York
10. Meltzer HY (1992) The mechanism of action of clozapine in relation to its clinical advantages. In: Meltzer HY (ed) Novel antipsychotic drugs. Raven Press, New York, pp 1-13
11. Montgomery S, Beasley CM, Tye NC (1992) Olanzapine: an open label study in schizophrenia. Second International Conference on Schizophrenia, Vancouver, BC, 19-22 July
12. Moore NA, Tye NC, Axton MS, Risius FC (1992) The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent. J Pharmacol Exp Ther 262:545-551
13. Moore NA, Calligaro DO, Wong TD, Bymaster F, Tye NC (1993) The pharmacology of olanzapine and other new antipsychotic agents. Curr Opin Invest Drugs 2:281-293
14. Moore NA, Rees G, Sanger G, Tye NC (1994) Effects of olanzapine and other antipsychotic agents on responding maintained by a conflict schedule. Behav Pharmacol 5:196-202
15. Rasmussen K, Stockton ME (1993) Olanzapine, a novel atypical antipsychotic, has electrophysiological effects on A9 and A10 dopamine neurons similar to clozapine. American College of Neuropsychopharmacology, Honolulu, Hawaii, 12-17 December
16. SAS Institute (1990) SAS/STAT user's guide, vol 1&2, 4th edn, 6th version. SAS Institute, Cary, New York
17. Seeman P, Van Toi HHM (1993) Dopamine receptor pharmacology. Curr Opin Neurol Neurosurg 6;602-608
18. Simpson GM, Angus JW (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212:11-19
19. Stockto ME, Rasmussen K (1993) A comparison of olanzapine and clozapine effects on dopamine neuronal activity: an electrophysiological study. Twenty-Third Annual Meeting of the Society for Neuroscience, Washington, DC, 7-12 November
20. Stockton ME, Rasmussen K (1995) Electrophysiological effects of olanzapine, a novel atypical antipsychotic, an A9 and A10 dopamine neurons. Neuropsychopharmacology (in press)
21. Tye NC, Moore NA, Rees G, Sanger G, Calligaro DO, Beasley CM (1992) Preclinical pharmacology of olanzapine: a novel "atypical" antipsychotic agent. Second International Conference on Schizophrenia, Vancouver, BC, 18-22 July
22. Wong DT, Moore NA, Calligaro O, Bymaster FP, Seeman P (1993) The preclinical pharmacology of olanzapine, a novel antipsychotic. Ninth World Congress of Psychiatry, Rio de Janeiro, Brazil, 6-12 June